ReviewDiabetes & metabolism journal2019
Nonalcoholic Fatty Liver Disease in Diabetes. Part I: Epidemiology and Diagnosis.
Review in Diabetes & metabolism journal, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 89 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
89 citing papers in PubMed, 5 syntheses or guidelines pooled it, 177 citations in OpenAlex.
- The prevalence of nonalcoholic fatty liver disease in people living with HIV: a systematic review and meta-analysis.BMC infectious diseases · 2025Pooled it
- Therapeutic outcome of dapagliflozin in patients with type 2 diabetes and non-alcoholic fatty liver disease: a meta-analysis of randomized controlled trials.African health sciences · 2023Pooled it
- Efficacy and Safety of GLP-1 Receptor Agonists in Patients With Type 2 Diabetes Mellitus and Non-Alcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis.Frontiers in endocrinology · 2021Pooled it
- Pioglitazone for NAFLD Patients With Prediabetes or Type 2 Diabetes Mellitus: A Meta-Analysis.Frontiers in endocrinology · 2021Pooled it
- Prevalence of Nonalcoholic Fatty Liver Disease (NAFLD) in Patients With Type 1 Diabetes Mellitus: A Systematic Review and Meta-Analysis.The Journal of clinical endocrinology and metabolism · 2020Pooled it
- Assessing the association of FIB-4 index with diabetic kidney disease in patients with diabetes mellitus: a cross-sectional and retrospective study utilizing NHANES and clinical data.Frontiers in endocrinology · 2026Article
- Concomitant Liver Biopsy During Bariatric Surgery: No Increase in Major Complications or Readmissions but Associated with Higher Transfusion Requirements - An Analysis of the MBSAQIP Database.Obesity surgery · 2025Article
- Review
- Fetuin-A as a Link Between Dyslipidemia and Cardiovascular Risk in Type 2 Diabetes: A Metabolic Insight for Clinical Practice.Biomedicines · 2025Article
- The association between diet quality and anthropometric measurements among non-alcoholic fatty liver disease patients with diabetes: a cohort-based cross-sectional study.BMC nutrition · 2025Article
- Hepatomegaly and Deranged Liver Enzymes in a Patient With Poorly Controlled Type 1 Diabetes Mellitus.JCEM case reports · 2025Article
- Metabolic Dysfunction-Associated Steatotic Liver Disease in the Korean General Population: Epidemiology, Risk Factors, and Non-Invasive Screening.Metabolites · 2025Review
- Combining nutraceuticals and a mediterranean diet for managing metabolic dysfunction associated with steatotic liver disease.World journal of hepatology · 2025Article
- Non-Alcoholic Fatty Liver Disease (NAFLD) Management in the Community.International journal of molecular sciences · 2025Review
- Creatinine-to-cystatin C ratio and all-cause and cardiovascular mortality in U.S. adults with nonalcoholic fatty liver disease: a nationwide cohort study.Frontiers in nutrition · 2025Article
- Assessing Nonalcoholic Fatty Liver Disease in Type 2 Diabetes Patients at a Tertiary Hospital, Addis Ababa, Ethiopia.Journal of diabetes research · 2025Article
- Metabolic Dysfunction-Associated Steatotic Liver Disease in Type 2 Diabetes Mellitus: A Review and Position Statement of the Fatty Liver Research Group of the Korean Diabetes Association.Diabetes & metabolism journal · 2024Review
- Autophagy alterations in obesity, type 2 diabetes, and metabolic dysfunction-associated steatotic liver disease: the evidence from human studies.Internal and emergency medicine · 2024Review
- Deploying a metabolic dysfunction-associated steatohepatitis consensus care pathway: findings from an educational pilot in three health systems.BMC primary care · 2024Article
- ZJU Index as a Predictive Tool for Diabetes Incidence: Insights from a Population-Based Cohort Study.Diabetes, metabolic syndrome and obesity : targets and therapy · 2024Article
29 more citing papers are in PubMed but not listed here.
Corrections and comments
- Erratum issued
Authors and funding
7 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Nonalcoholic fatty liver disease (NAFLD) and diabetes are common metabolic disorders whose prevalence rates are expected to rise worldwide, corresponding to aging and increasingly obese populations. Compared to the general population (around 25%), 50% to 70% of people with diabetes have NAFLD, and NAFLD severity (including fibrosis) tends to be worsened by the presence of diabetes. NAFLD is considered an emerging risk factor for type 2 diabetes mellitus and a contributor to the development of chronic diabetes-related complications. This reciprocal relationship demonstrates the importance of confirming suspected NAFLD in patients with diabetes. Due to the invasive nature of liver biopsy to assess NAFLD status, various alternative non-invasive modalities have been developed and validated. Here, we summarized the epidemiology of NAFLD in patients with diabetes and reviewed currently available imaging modalities and biomarker-based prediction models for their ability to detect liver steatosis and/or fibrosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.